Effect of tunicamycin on receptors for tumor promoters

V. Solanki; M. K. Logani; T. J. Slaga

doi:10.1016/0304-3835(82)90013-1

Effect of tunicamycin on receptors for tumor promoters

V. Solanki, M. K. Logani, T. J. Slaga

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A progressive decline in the specific binding of [20-³H]phorbol 12,13-dibutyrate ([³H]PDBu) and glycoprotein synthesis was observed following treatment of primary mouse epidermal cells with tunicamycin, a specific inhibitor of dolichol-mediated glycosylation. Following 18 h of treatment, the specific binding of [³H]PDBu was reduced to 33-56% of the control value. The total protein synthesis determined by leucine incorporation into acid-insoluble material was not altered by this antibiotic drug. These results suggest that the receptor for phorbol diesters is, or is functionally linked to, a glycoprotein on the cell surface.

Original language	English (US)
Pages (from-to)	319-325
Number of pages	7
Journal	Cancer Letters
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/0304-3835(82)90013-1
State	Published - Sep 1982
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/0304-3835(82)90013-1

Fingerprint Dive into the research topics of 'Effect of tunicamycin on receptors for tumor promoters'. Together they form a unique fingerprint.

Cite this

@article{b42f015267264d799e3080095c6ace31,

title = "Effect of tunicamycin on receptors for tumor promoters",

abstract = "A progressive decline in the specific binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDBu) and glycoprotein synthesis was observed following treatment of primary mouse epidermal cells with tunicamycin, a specific inhibitor of dolichol-mediated glycosylation. Following 18 h of treatment, the specific binding of [3H]PDBu was reduced to 33-56% of the control value. The total protein synthesis determined by leucine incorporation into acid-insoluble material was not altered by this antibiotic drug. These results suggest that the receptor for phorbol diesters is, or is functionally linked to, a glycoprotein on the cell surface.",

author = "V. Solanki and Logani, {M. K.} and Slaga, {T. J.}",

year = "1982",

month = sep,

doi = "10.1016/0304-3835(82)90013-1",

language = "English (US)",

volume = "16",

pages = "319--325",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "3",

}

TY - JOUR

T1 - Effect of tunicamycin on receptors for tumor promoters

AU - Solanki, V.

AU - Logani, M. K.

AU - Slaga, T. J.

PY - 1982/9

Y1 - 1982/9

N2 - A progressive decline in the specific binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDBu) and glycoprotein synthesis was observed following treatment of primary mouse epidermal cells with tunicamycin, a specific inhibitor of dolichol-mediated glycosylation. Following 18 h of treatment, the specific binding of [3H]PDBu was reduced to 33-56% of the control value. The total protein synthesis determined by leucine incorporation into acid-insoluble material was not altered by this antibiotic drug. These results suggest that the receptor for phorbol diesters is, or is functionally linked to, a glycoprotein on the cell surface.

AB - A progressive decline in the specific binding of [20-3H]phorbol 12,13-dibutyrate ([3H]PDBu) and glycoprotein synthesis was observed following treatment of primary mouse epidermal cells with tunicamycin, a specific inhibitor of dolichol-mediated glycosylation. Following 18 h of treatment, the specific binding of [3H]PDBu was reduced to 33-56% of the control value. The total protein synthesis determined by leucine incorporation into acid-insoluble material was not altered by this antibiotic drug. These results suggest that the receptor for phorbol diesters is, or is functionally linked to, a glycoprotein on the cell surface.

UR - http://www.scopus.com/inward/record.url?scp=0019959080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019959080&partnerID=8YFLogxK

U2 - 10.1016/0304-3835(82)90013-1

DO - 10.1016/0304-3835(82)90013-1

M3 - Article

C2 - 6295623

AN - SCOPUS:0019959080

VL - 16

SP - 319

EP - 325

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 3

ER -